ViaCell, Incannounced today the United States Food and Drug Administration (FDA) has conditionally approved its Investigational Device Exemption (IDE) to evaluate its ViaCyte(SM) investigational product offering for the cryopreservation and thawing of human
oocytes for use during assisted reproductive technology.
ViaCell
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
FDA Warns Becton Dickinson for Potentially Contaminated Water, Environmental Conditions
The company promised to discontinue use of tap water.
FDA Releases 25 Product-Specific Guidances for Generics
“In too many cases, there is no generic competition for these costly branded drugs even after they have lost their exclusivity protections,” said FDA Commissioner Scott Gottlieb.
FDAnews Device Daily Bulletin
VIACELL FINALIZES IDE AND ANNOUNCES PLANS TO COMMENCE CLINICAL TRIAL OF VIACYTE IN OOCYTE CRYOPRESERVATION
June 28, 2006